Voices
Recent Research on Extended Reduced-Dose Apixaban for Cancer-Associated VTE – MASCC
Mélanie Janson

Recent Research on Extended Reduced-Dose Apixaban for Cancer-Associated VTE – MASCC

The Multinational Association of Supportive Care in Cancer (MASCC) shared a post on LinkedIn:

“In this edition of the Supportive Care Digest, Mélanie Janson summarizes recent research on extended reduced-dose apixaban for cancer-associated venous thromboembolism.

Watch now.”

Recent Research on Extended Reduced-Dose Apixaban for Cancer-Associated VTE - MASCC

Other articles from MASCC on OncoDaily.

cancer MASCC Mélanie Janson OncoDaily Oncology